Clinical trials: JIA
Juvenile Idiopathic Arthritis
Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis
The primary objective of this study is to evaluate the pharmacokinetics (PK) of olokizumab (OKZ) in patients with polyarticular juvenile idiopathic arthritis aged >2 and <18 years in two doses (64 mg or 48 mg every 4 weeks)…
- Trial name
- NCT07517575
- Testing
- OKZ q4w
- Where
- 14 sites in Russia
- Volunteers
- 71 people
- Sponsor
- R-Pharm International, LLC
Juvenile Idiopathic Arthritis
Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA)
This study investigates the efficacy of probiotic VSL#3 as an add on standard care on the activity of the disease in patients with Juvenile Idiopathic Arthritis.
- Trial name
- PERMAJI (NCT03092427)
- Testing
- VSL#3
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Juvenile Idiopathic Arthritis
A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)
This Phase IV, multicenter, single-arm, open-label study will evaluate the efficacy and safety of tocilizumab in Chinese participants with sJIA with persistent activity and an inadequate response to non-steroidal…
- Trial name
- NCT03301883
- Testing
- Tocilizumab, NSAIDs, CSs
- Where
- 10 sites in China
- Volunteers
- 62 people
- Sponsor
- Hoffmann-La Roche
Juvenile Idiopathic Arthritis, COVID 19
Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment
The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates…
- Conditions
- Juvenile Idiopathic Arthritis, COVID 19, Treatment
- Trial name
- RHUMAJICOVID (NCT04407923)
- Where
- 8 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Brest
Polyarticular Juvenile Rheumatoid Arthritis, Arthritis, Juvenile Idiopathic
Start Time Optimization of Biologics in Polyarticular JIA
STOP-JIA is a PCORI funded prospective observational study which compared the clinical effectiveness and impact on patient reported outcomes of 3 Childhood Arthritis \& Rheumatology Research Alliance (CARRA) consensus derived…
- Trial name
- STOP-JIA (NCT02593006)
- Where
- 55 sites in United States, Canada
- Volunteers
- 400 people
- Sponsor
- Hackensack Meridian Health
Spinal Cord Injuries, Spina Bifida
Examining Capacity Building of Youth With Physical Disabilities to Pursue Participation Following the PREP Intervention.
The goal of this clinical trial is to learn about how a participation-based intervention builds capacity of youth with physical disabilities to pursue activities of their choice in the community.
- Conditions
- Spinal Cord Injuries, Spina Bifida, Musculoskeletal Disorder, Juvenile Arthritis
- Trial name
- NCT06007885
- Testing
- Pathways and Resources to Engagement and Participation (PREP)
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- McGill University
Juvenile Idiopathic Arthritis
Patient Centered Adaptive Treatment Strategies Using Bayesian Causal Inference
The best treatment plan for Juvenile Idiopathic Arthritis (JIA) is often complicated. Patients and clinicians often don't know what is the best treatment strategy for a given patient at a given time.
- Trial name
- NCT02524340
- Where
- United States
- Volunteers
- 465 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Glucocorticoid-Associated Osteopenia and Osteoporosis
Alendronate Osteoporosis Study
This trial will test the hypothesis that among 20 children and adolescents from Children's Hospital, Boston with Crohn's disease, ulcerative colitis, systemic-onset juvenile rheumatoid arthritis, juvenile dermatomyositis…
- Trial name
- NCT00277251
- Testing
- Alendronate
- Volunteers
- 20 people
- Sponsor
- Boston Children's Hospital
Polyarticular Juvenile Idiopathic Arthritis
An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Pediatric Participants With Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease affecting children, characterized by chronic synovitis with systemic multi-organ damage.
- Trial name
- NCT05411211
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- AbbVie
Juvenile Idiopathic Arthritis
Clinical, Laboratory and Ultrasound Stratification of Patients With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis (JIA), the most common rheumatologic chronic disease in children, is defined as arthritis persisting for at least 6 weeks with no known cause in a patient under the age of 16.
- Trial name
- NCT06007456
- Where
- 2 sites in Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS Burlo Garofolo
Juvenile Idiopathic Arthritis
A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)
PART1 Participants in Part 1 (Run-in-Phase) of study will receive tocilizumab (TCZ) (RoActemra/Actemra) 12 milligrams per kilogram (mg/kg) or 8 mg/kg intravenously (IV) every 2 weeks (Q2W) for up to 24 weeks.
- Trial name
- NCT01734382
- Testing
- Tocilizumab
- Where
- 19 sites in United States, Argentina and 8 more
- Volunteers
- 35 people
- Sponsor
- Hoffmann-La Roche
Juvenile Idiopathic Arthritis, Malocclusion, Angle Class II
Mandibular Advancement Clear Aligner Treatment in Juvenile Idiopathic Arthritis Subjects
There is currently no information on how mandibular advancement therapy could influence three-dimensionally the condylar and mandibular morphology in growing patients affected by Juvenile Idiopathic Arthritis (JIA).
- Trial name
- NCT05467579
- Testing
- Device: orthodontic - mandibular advancement clear aligner
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Genova
Juvenile Idiopathic Arthritis, Familial Mediterranean Fever
Assessment of Cardiorespiratory Fitness Using the PACER in Patients With Juvenile Idiopathic Arthritis and Familial Mediterranean Fever
Juvenile Idiopathic Arthritis (JIA) and Familial Mediterranean Fever (FMF) are the most common autoimmune and autoinflammatory rheumatic diseases in childhood.
- Conditions
- Juvenile Idiopathic Arthritis, Familial Mediterranean Fever, Healty Controls
- Trial name
- NCT06697028
- Testing
- Usability and Comparison
- Where
- Turkey (Türkiye)
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
Chronic Pain
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects
The purpose of this study is to evaluate the effectiveness, tolerability, and safety of oxymorphone immediate release (IR) oral liquid as an analgesic in pediatric subjects having severe to moderate chronic pain.
- Trial name
- NCT01206907
- Testing
- oxymorphone IR
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Septic Arthritis, Juvenile Idiopathic Arthritis
ARTEMIS Synovial Markers in Arthritis Childhood
The aim of this study is to find markers that could differentiate infectious and inflammatory arthritis. The investigators want to find markers by differential analysis by compare synovial fluids of septic and inflammatory…
- Trial name
- ARTEMIS (NCT02505828)
- Testing
- Articular punction, salivary samples, blood sample
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Montpellier
Systemic Juvenile Idiopathic Arthritis
An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
This two-part open-label, multi-arm, non-comparative study will collect long-term safety, efficacy and tolerability data from patients who were responsive to canakinumab from study CACZ885G2301E1 (Cohort 1), and from patients who…
- Trial name
- β-SPECIFIC 4Pa (NCT01676948)
- Testing
- ACZ885, Canakinumab
- Sponsor
- Novartis Pharmaceuticals
Juvenile Idiopathic Arthritis, ALL
Understanding Methotrexate Induced Gastrointestinal Intolerance in Juvenile Idiopathic Arthritis and Childhood Leukemia
Methotrexate is a cornerstone in the treatment of childhood leukemia. When given in high-dose as part of the initial phase of treatment, gastrointestinal toxicity is a known problem.
- Trial name
- NCT02528435
- Volunteers
- 145 people
- Sponsor
- University of Aarhus
Juvenile Idiopathic Arthritis
Biomarkers in Saliva in Children With Juvenil Idiopathic Arthritis
Purpose and aims This as a pilot study that aims to investigate which inflammatory biomarkers can be found in saliva in children with Juvenile Idiopathic Arthritis (JIA).
- Trial name
- NCT02223195
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Folktandvården Stockholms län AB
Juvenile Idiopathic Arthritis
Cellular and Molecular Adaptations to Exercise-induced Inflammatory Response in Children With Autoimmune Diseases
Juvenile idiopathic arthritis (JIA) is a chronic disease characterized by persistent joint inflammation. The immune system disruption that leads to overproduction of pro-inflammatory cytokines (TNF-α, IL-1, IL-6) is a cascade of…
- Trial name
- AJI-APA (NCT02502539)
- Testing
- Controlled physical activity
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Clermont-Ferrand
Juvenile Idiopathic Arthritis
Pain in Juvenile Arthritis
Juvenile idiopathic arthritis (JIA) is the most common rheumatologic disease in children. The main symptoms of JIA, which are often the primary focus of treatment, include joint swelling, stiffness, and tenderness.
- Trial name
- NCT07217782
- Testing
- Pressure pain thresholds (measured in kilopascal), Cold pain tolerance (duration in seconds)
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine